Logo image of ZIOP

ZIOPHARM ONCOLOGY INC (ZIOP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZIOP - Common Stock

0.8657
-0.01 (-0.88%)
Last: 1/26/2022, 8:08:27 PM
0.88
+0.01 (+1.65%)
After Hours: 1/26/2022, 8:08:27 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ZIOP. ZIOP was compared to 530 industry peers in the Biotechnology industry. ZIOP has a bad profitability rating. Also its financial health evaluation is rather negative. ZIOP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ZIOP has reported negative net income.
ZIOP Yearly Net Income VS EBIT VS OCF VS FCFZIOP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -78.87%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZIOP Yearly ROA, ROE, ROICZIOP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -100 -200 -300

1.3 Margins

ZIOP does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -22543.47%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZIOP Yearly Profit, Operating, Gross MarginsZIOP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

ZIOP has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ZIOP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZIOP Yearly Shares OutstandingZIOP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M
ZIOP Yearly Total Debt VS Total AssetsZIOP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M

2.2 Solvency

ZIOP has an Altman-Z score of -9.61. This is a bad value and indicates that ZIOP is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.18 indicates that ZIOP is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -9.61
ROIC/WACCN/A
WACCN/A
ZIOP Yearly LT Debt VS Equity VS FCFZIOP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.43 indicates that ZIOP has no problem at all paying its short term obligations.
ZIOP has a Quick Ratio of 3.43. This indicates that ZIOP is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 3.43
ZIOP Yearly Current Assets VS Current LiabilitesZIOP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

ZIOP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.22%.
EPS 1Y (TTM)-16.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZIOP will show a small growth in Earnings Per Share. The EPS will grow by 0.12% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.87%
EPS Next 2Y5.92%
EPS Next 3Y-0.45%
EPS Next 5Y0.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZIOP Yearly Revenue VS EstimatesZIOP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2M 4M 6M
ZIOP Yearly EPS VS EstimatesZIOP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZIOP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZIOP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZIOP Price Earnings VS Forward Price EarningsZIOP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.38
ZIOP Per share dataZIOP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.92%
EPS Next 3Y-0.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZIOP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZIOPHARM ONCOLOGY INC

NASDAQ:ZIOP (1/26/2022, 8:08:27 PM)

After market: 0.88 +0.01 (+1.65%)

0.8657

-0.01 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners2.76%
Ins Owner Change0%
Market Cap187.12M
Revenue(TTM)398.00K
Net Income(TTM)-89.72M
Analysts75.38
Price Target4 (362.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 470.14
P/FCF N/A
P/OCF N/A
P/B 2.72
P/tB N/A
EV/EBITDA -1.38
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.32
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -22543.47%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 3.43
Altman-Z -9.61
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y-3.87%
EPS Next 2Y5.92%
EPS Next 3Y-0.45%
EPS Next 5Y0.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ZIOPHARM ONCOLOGY INC / ZIOP FAQ

What is the fundamental rating for ZIOP stock?

ChartMill assigns a fundamental rating of 1 / 10 to ZIOP.


What is the valuation status for ZIOP stock?

ChartMill assigns a valuation rating of 1 / 10 to ZIOPHARM ONCOLOGY INC (ZIOP). This can be considered as Overvalued.


How profitable is ZIOPHARM ONCOLOGY INC (ZIOP) stock?

ZIOPHARM ONCOLOGY INC (ZIOP) has a profitability rating of 0 / 10.


How financially healthy is ZIOPHARM ONCOLOGY INC?

The financial health rating of ZIOPHARM ONCOLOGY INC (ZIOP) is 2 / 10.